This NDC is on FDA's drug shortage list (posted Mar 13, 2023)

Reported reason: Other

Product Information

METHOTREXATE 50 MG/2 ML VIAL is a generic product labeled by Hospira Inc., priced at $3.1248 per ML under NDC 61703016105. Its NADAC has been published 96 times since Jan 15, 2025.

FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.

METHOTREXATE 50 MG/2 ML VIAL

Methotrexate
$3.1248per ML

Strength

25 mg/mL

Manufacturer

Hospira Inc.

NDC

61703016105

Classification

Generic

Dosage Form

INJECTION, SOLUTION

Route

INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS

Effective Date

10/21/2026

Active Ingredients

METHOTREXATE SODIUM

Approval Type

New Drug (NDA)

FDA Application

NDA011719

FDA Approved

Before 1982

TE Code

AP

On Market Since

11/4/2024

Pharmacological Classes

Folate Analog Metabolic Inhibitor
Folic Acid Metabolism Inhibitors

Price Statistics

The NADAC for METHOTREXATE 50 MG/2 ML VIAL has been published 96 times since Jan 15, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$3.1248 per ML
All-time high$3.3602 (Jun 10, 2026)
All-time low$2.9679 (Jun 18, 2025)
52-week high$3.3602
52-week low$3.1248
Median price$3.1788
Average price$3.1799
Largest weekly change+4.1% (Sep 17, 2025)
Weeks tracked96
Tracking sinceJan 15, 2025

Price History

1W

0.0%

1M

-1.8%

3M

-3.8%

6M

-6.7%

1Y

-2.7%

3Y

N/A

5Y

N/A

All

+1.0%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 79% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of METHOTREXATE 50 MG/2 ML VIAL?

The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 50 MG/2 ML VIAL, manufactured by Hospira Inc., is $3.1248 per ML (NDC 61703016105), effective Nov 11, 2026.

How has the price of METHOTREXATE 50 MG/2 ML VIAL changed over time?

Over the history we have for it, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has held within roughly two percent of its current level. It has been tracked across 96 weekly CMS publications since Jan 15, 2025.

What are the highest and lowest recorded NADAC prices for METHOTREXATE 50 MG/2 ML VIAL?

Since Jan 15, 2025, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has ranged from a low of $2.9679 (Jun 18, 2025) to a high of $3.3602 (Jun 10, 2026), with a median of $3.1788 per ML.

Are there cheaper alternatives to METHOTREXATE 50 MG/2 ML VIAL?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHOTREXATE 1 GRAM/40 ML VIAL, is $0.6450 per ML — about 79% below METHOTREXATE 50 MG/2 ML VIAL.

Who manufactures METHOTREXATE 50 MG/2 ML VIAL?

METHOTREXATE 50 MG/2 ML VIAL (NDC 61703016105) is labeled by Hospira Inc., and CMS classifies it as a generic product.

Is METHOTREXATE 50 MG/2 ML VIAL in shortage?

Yes — NDC 61703016105 is currently listed in FDA's drug shortage database (posted Mar 13, 2023). Reported reason: Other.